Investor Relations

Latest Financial Results

FY 2021

Fiscal Year Ended Dec 31, 2021

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

XORTX Therapeutics Inc. is a pharmaceutical company, developing drug based products for two clinically advanced products – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.

Stock Snapshot

XORTX Therapeutics Inc.

View Detailed Stock Information

IR Contacts


XORTX Therapeutics Inc.
4000, 421 - 7th Avenue SW
Calgary, Alberta T2P 4K9
T: 403-455-7727

Investor Relations

Allen Davidoff
T: 403-455-7727

Nick Rigopulos
Director of Communications
T: 617-901-0785

Transfer Agent

TSX Trust Company
Investor Services
100 Adelaide Street West
Suite 301
Toronto, ON M5H 4H1
T: 416-342-1091